Diazepam Nasal Spray

Introduction Overview

Generic Name

diazepam nasal spray

Brand Name

Valtoco

Dosage Form

nasal spray (5 mg, 7.5 mg, 10 mg)

Drug Class

Benzodiazepine anticonvulsants

Pharmacokinetics

Absorption:
Valtoco, administered as a nasal spray, provides rapid absorption of diazepam through the highly vascularized nasal mucosa. This route bypasses the gastrointestinal tract, allowing for a faster onset of action crucial for acute seizure cluster treatment. Clinical pharmacokinetic studies indicate that peak plasma concentrations are typically reached within an hour post-administration, with effective systemic levels achieved rapidly to abort seizure clusters. Absorption can be influenced by nasal mucosal conditions such as congestion or inflammation, potentially affecting drug bioavailability.

Distribution:
Diazepam exhibits extensive distribution following absorption, characterized by high lipophilicity enabling its penetration into various tissues including the central nervous system (CNS). The volume of distribution ranges between 0.8 to 1.0 L/kg, demonstrating significant tissue binding, especially in adipose tissue. Diazepam crosses the blood-brain barrier efficiently, exerting its action within the CNS. It also crosses the placental barrier and is excreted into breast milk. Diazepam is highly protein-bound (approximately 98%), primarily to albumin, which is an important consideration in conditions that alter plasma proteins.

Metabolism:
Metabolism of diazepam occurs predominantly in the liver via cytochrome P450 enzymes, mainly CYP2C19 and CYP3A4 isoforms. Diazepam is biotransformed into active metabolites, including desmethyldiazepam (nordiazepam), temazepam, and oxazepam, all of which possess pharmacologic activity, contributing to the drug’s sustained effects and half-life. These metabolites exhibit slower elimination and can accumulate, especially with repeated dosing. Genetic polymorphisms affecting CYP2C19 can influence metabolism rates, potentially altering efficacy and safety profiles.

Elimination:
Diazepam and its metabolites are eliminated primarily through renal excretion following hepatic metabolism. The elimination half-life of diazepam ranges between 20 to 50 hours, extended in certain populations such as the elderly or those with hepatic impairment. The prolonged half-life allows for sustained anticonvulsant activity but necessitates cautious dosing to avoid accumulation and toxicity. Clearance may be reduced in hepatic or renal dysfunction, requiring dose adjustments. Elimination kinetics support the use of Valtoco for intermittent seizure clusters rather than chronic daily management.

Dosage Forms

Available Dosage Forms:
Valtoco is available exclusively as a nasal spray in three different strengths: 5 mg/0.1 mL, 7.5 mg/0.1 mL, and 10 mg/0.1 mL formulations. Each nasal spray device delivers a single dose and is intended for one-time use, providing a non-invasive, rapid delivery option for acute seizure cluster management.

Dosages for Adults and Adolescents:
Dosing is weight and age-dependent for individuals 2 years and older. The recommended dose is calculated on a mg/kg basis, with dosing tiers as follows: 0.5 mg/kg for ages 2-5 years, 0.3 mg/kg for ages 6-11 years, and 0.2 mg/kg for patients aged 12 and older. Specific device counts per dose are based on weight brackets across these age groups, ranging from one 5 mg device for lighter weights up to two 10 mg devices for heavier patients, administered as nasal sprays either unilaterally or bilaterally depending on required dosage.

Specific Patient Populations:
Valtoco dosing requires careful consideration in pediatric patients aged 2 years and older, with no current recommendations for those under 2 years due to insufficient safety and efficacy data. In elderly patients or those with hepatic or renal impairment, the drug’s long half-life and active metabolites necessitate cautious use, though specific dosing adjustments are not definitively established and should be individualized. Since diazepam is a controlled substance with risks for dependence and sedation, all patients should be monitored closely. Use during pregnancy and breastfeeding is contraindicated or advised against due to risks to the fetus or infant. Valtoco is also contraindicated in patients with acute narrow-angle glaucoma.

Mechanism Of Action

Valtoco delivers diazepam, a benzodiazepine, directly to the central nervous system via nasal absorption where it exerts its anticonvulsant effects. Mechanistically, diazepam acts as a positive allosteric modulator of the gamma-aminobutyric acid type A (GABAA) receptor complex, the principal inhibitory neurotransmitter receptor in the CNS. By binding to specific benzodiazepine sites on these receptors, diazepam enhances GABA-mediated chloride ion influx, increasing neuronal membrane hyperpolarization and stabilizing neuronal excitability.

This potentiation of GABA inhibitory effects leads to suppression of abnormal electrical activity responsible for seizures. Diazepam’s facilitation of GABAA receptor function results in decreased neuronal firing rates, diminished synaptic transmission of excitatory signals, and reduced seizure propagation. Its rapid onset following nasal administration is critical for aborting acute repetitive seizures.

Diazepam’s receptor modulation differs from other anticonvulsants that may act on sodium channels, calcium channels, or glutamate receptors, providing a unique mechanism focused on enhancing inhibitory pathways. Research and clinical trials support its efficacy in rapidly terminating seizure clusters and reducing seizure recurrence when promptly administered.

Additionally, diazepam exhibits muscle relaxant, anxiolytic, and sedative properties due to its broad CNS depressant actions. This multifaceted mechanism explains both its therapeutic anticonvulsant benefits and the sedation-related side effects observed clinically. Its pharmacodynamic profile necessitates careful dosage and monitoring to balance seizure control with tolerability and safety.

Pharmacological Actions

Acts as a benzodiazepine anticonvulsant enhancing inhibitory neurotransmission via GABAA receptor modulation.
Exerts rapid anticonvulsant effects by potentiation of GABA-induced chloride influx leading to neuronal hyperpolarization.
Provides muscle relaxant and anxiolytic effects due to CNS depressant activity.
Aborts acute repetitive seizures by stabilizing neuronal excitability and preventing seizure spread.
Reduces seizure cluster frequency and severity when administered promptly.
Possesses sedative properties that can induce drowsiness and impair motor coordination.
Displays CNS depressant effects that can potentiate respiratory depression especially with other depressants.
Has active metabolites contributing to prolonged pharmacologic actions and half-life.
Capable of producing physical dependence and withdrawal symptoms upon abrupt cessation.
Functions as a Schedule IV controlled substance with abuse potential.
Exhibits anxiolytic and hypnotic properties relevant to associated neurological symptom management.
Displays high lipophilicity facilitating CNS penetration after nasal administration.
Interacts with opioid medications to increase risk of respiratory depression.
Binds extensively to plasma proteins influencing distribution and elimination.
Influences calcium channel-mediated neurotransmitter release indirectly via GABA modulation.

Therapeutic Or Clinical Uses

Acute (immediate) treatment of intermittent seizure clusters (acute repetitive seizures) in patients aged 2 years and older.
Rapid abortive therapy to stop seizure clusters different from patient's usual seizure pattern.
Non-invasive nasal administration suitable when intravenous or oral routes are impractical.
Management of seizure emergencies in outpatient or home settings to reduce hospitalization.
Rescue therapy to prevent progression to status epilepticus.
Supplemental therapy adjunct to chronic antiseizure medications.
Treatment option when rapid onset of anticonvulsant action is required.
Emergency seizure control in patients with established epilepsy prone to cluster seizures.
Useful in pediatric populations above 2 years with recurrent seizure episodes.
Alternative to rectal diazepam for seizure emergencies providing easier administration.
Quick reversal of seizure activity while minimizing systemic side effects.
Lower risk route of administration compared to intravenous formulations during seizure episodes.
Provision for second dose administration if seizures persist after initial treatment.
Compatible with concurrent use of various anti-epileptic drugs under medical supervision.
Applicable in outpatient rescue kits for seizure-prone individuals and their caregivers.

Side Or Adverse Effects

Common side effects include drowsiness and somnolence.
Headache and nasal discomfort following nasal administration.
Sedation leading to impaired alertness, coordination, and motor skills.
Risk of respiratory depression, especially when combined with opioids, alcohol, or CNS depressants.
Potential for physical dependence, tolerance, and withdrawal symptoms.
Serious adverse reactions such as coma, paralysis, or excessive sedation upon misuse or overdose.
Paradoxical reactions including agitation, aggression, and suicidal thoughts.
Cognitive impairment affecting memory, concentration, and mood.
Increased intraocular pressure contraindicating use in narrow-angle glaucoma.
Possible allergic reactions or hypersensitivity to diazepam or excipients.
Withdrawal symptoms on abrupt discontinuation including seizures, irritability, tremors.
Rare reports of severe respiratory failure with concomitant depressants.
Potential for abuse and addiction necessitating careful use and storage.
Neonatal withdrawal symptoms if used during late pregnancy.
Transient dizziness and vertigo post administration.

Precautions

Use cautiously in patients with respiratory disorders such as asthma, COPD, or bronchitis.
Monitor for signs of abuse, dependence, or addiction especially in patients with substance use history.
Avoid concurrent use with opioids, alcohol, or other CNS depressants without strict medical supervision.
Do not abruptly discontinue to prevent withdrawal seizures and neuropsychiatric reactions.
Exercise caution in patients with hepatic or renal impairment due to altered metabolism and elimination.
Monitor closely for mood changes or emergence of suicidal ideation or behavior during treatment.
Use only as prescribed and counsel patients on proper use and storage to prevent misuse.
Avoid use in patients with narrow-angle glaucoma.
Pregnant and breastfeeding women should avoid use due to fetal/infant risks.
Avoid activities requiring mental alertness until drug effects are known (e.g., driving, operating machinery).
Inform healthcare providers of all concomitant medications to prevent interactions.
Caregivers administering the drug should be trained in usage and emergency procedures.
Maintain secure storage to prevent accidental ingestion or diversion.
Limit frequency of dosing to no more than 1 seizure cluster episode every 5 days and 5 episodes per month.
Assess patients for potential drug interactions regularly.

Warnings

Boxed Warning for risks associated with concomitant use with opioids including severe sedation, respiratory depression, coma, and death.
Warning for abuse, misuse, addiction, and associated overdose risks.
Risk of physical dependence and serious withdrawal reactions after prolonged or frequent use.
Not intended for daily use; excessive use increases adverse effect risks.
Potential for suicidal thoughts and behaviors; close monitoring required.
Risk of increased intraocular pressure; contraindicated in narrow-angle glaucoma.
Avoid use if signs of respiratory depression or compromised breathing are present.
Second dose should not be administered if extreme drowsiness or breathing difficulties occur.
Use with caution in patients with depression or mental health disorders.
Do not share medication to prevent harm and legal consequences.
May cause CNS depression affecting mental and motor skills.
Pregnancy-associated risks including neonatal sedation and withdrawal.
Potential for severe adverse CNS effects in overdose situations.
Ensure emergency medical support is accessible when administering.
Use in children under 2 years is not approved due to safety concerns.

Contraindication

Known allergy or hypersensitivity to diazepam, Valtoco formulation, or benzodiazepines.
Acute narrow-angle glaucoma.
Severe respiratory insufficiency or respiratory depression without ventilatory support.
Myasthenia gravis due to exacerbation of muscle weakness.
Severe hepatic dysfunction or hepatic failure.
Use with concomitant use of other CNS depressants without supervision.
History of diazepam hypersensitivity or anaphylactoid reactions.
Pregnancy unless benefits outweigh risks, due to potential fetal harm.
Breastfeeding unless alternative feeding options are available.
Severe sedative or hypnotic drug intoxication with respiratory depression.
Patients with untreated sleep apnea syndrome.
Concomitant use with alcohol or illicit CNS depressants.
Known or suspected substance abuse disorders without regulatory compliance.
Infants less than 2 years of age due to lack of established safety.

Drug Interactions

Additive CNS depressant effects when combined with opioids, increasing risk of respiratory depression and death.
Increased sedation and dizziness with concurrent use of alcohol, muscle relaxants, or sleep aids.
Metabolic interactions with CYP3A4 and CYP2C19 inhibitors or inducers altering diazepam plasma levels.
Potential for increased toxicity with concomitant use of other benzodiazepines or anticonvulsants.
Interactions with certain antidepressants that potentiate sedative or cognitive side effects.
Enhanced respiratory depression risk with concomitant use of other CNS depressants including antipsychotics and anesthetics.
Possible pharmacodynamic interaction with medications affecting GABAergic neurotransmission.
Reduced clearance in presence of inhibitors such as cimetidine or ketoconazole.
Potential for altered therapeutic effects when used with anticonvulsants like phenytoin or valproate.
Warfarin interaction risk is minimal but caution warranted with anticoagulants.
Interactions with herbal supplements such as St. John’s Wort affecting metabolism.
Drugs that impair hepatic function may increase diazepam half-life.
Avoid simultaneous use with drugs that prolong sedation to prevent accidents.
Some antivirals and antibiotics may inhibit diazepam metabolism leading to accumulation.
Caution when combined with drugs that lower seizure threshold.

Preparations Of The Drug

Valtoco nasal spray available in single-use nasal spray devices containing 5 mg/0.1 mL diazepam.
Valtoco nasal spray available in 7.5 mg/0.1 mL single-use devices, dosed according to weight and age.
Valtoco nasal spray available in 10 mg/0.1 mL single-use devices for higher weight dosing.
Each device intended for one-time intranasal administration delivering a single dose.
Packaging includes protective blister packs maintaining drug stability and light protection.
Devices designed to deliver one spray per application; no priming or testing prior to use.
Dosing involves unilateral or bilateral nasal administration depending on dose size.
Inactive ingredients include benzyl alcohol, dehydrated alcohol, n-dodecyl beta-D-maltoside, and vitamin E for formulation stability.
Stored at controlled room temperature (20°C to 25°C) avoiding freezing and light exposure.
Supplied in individual packages to facilitate ease of carrying and emergency use.
Manufactured by Neurelis, Inc., ensuring consistent pharmaceutical quality standards.
Provided with detailed patient instructions for proper use and disposal to prevent misuse.
Each dose pack includes a precise quantity to avoid dosing errors during seizure emergencies.
Formulated to allow rapid systemic absorption through nasal mucosa.
Devices are federally controlled (Schedule IV) and must be stored securely.